Current management in polycythemia vera
- 1 January 2001
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 38, 25-28
- https://doi.org/10.1016/s0037-1963(01)90137-4
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Long term treatment of myeloproliferative disease with interferon-?-2bCancer, 1998
- Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Cases With 17p DeletionBlood, 1998
- Therapeutic Dilemmas: Balancing the Risks of Bleeding, Thrombosis, and Leukemic Transformation in Myeloproliferative Disorders (MPD)Thrombosis and Haemostasis, 1997
- Risk of Leukaemia, Carcinoma, and Myelofibrosis in32P- or Chemotherapy-Treated Patients with Polycythaemia Vera: a Prospective Analysis of 682 CasesLeukemia & Lymphoma, 1996
- AnagrelideDrugs, 1994
- Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implicationsEuropean Journal of Haematology, 1994
- Anagrelide, a therapy for thrombocythemic states: Experience in 577 patientsThe American Journal of Medicine, 1992
- A new treatment for polycythemia vera: recombinant interferon alfa [see comments]Blood, 1990
- Anagrelide: A potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activityBiochemical Pharmacology, 1988
- Anagrelide: A New Drug for Treating ThrombocytosisNew England Journal of Medicine, 1988